Introduction {#bjs10954-sec-0005}
============

Treatment for acute lower limb ischaemia (ALI) represents a major challenge for vascular specialists, largely because of high amputation and death rates[1](#bjs10954-bib-0001){ref-type="ref"}, [2](#bjs10954-bib-0002){ref-type="ref"}, [3](#bjs10954-bib-0003){ref-type="ref"}, [4](#bjs10954-bib-0004){ref-type="ref"}, [5](#bjs10954-bib-0005){ref-type="ref"}. The 1‐year amputation‐free survival rate is approximately 50--70 per cent[6](#bjs10954-bib-0006){ref-type="ref"}, [7](#bjs10954-bib-0007){ref-type="ref"}. The optimal choice of treatment remains undefined despite considerable research effort[8](#bjs10954-bib-0008){ref-type="ref"}. Previous reports[9](#bjs10954-bib-0009){ref-type="ref"}, [10](#bjs10954-bib-0010){ref-type="ref"}, [11](#bjs10954-bib-0011){ref-type="ref"}, [12](#bjs10954-bib-0012){ref-type="ref"} highlighted that differences in outcome are dependent on the aetiology of the occlusion: either arterial thrombosis, embolus or aneurysm. These aetiologies may represent different diseases, with mutual symptoms, but requiring different treatment for optimal outcome[4](#bjs10954-bib-0004){ref-type="ref"}.

Open surgery was previously the exclusive treatment option. After the advent of catheter‐directed thrombolytic therapy, its use was compared with open surgery in several RCTs in the mid‐1990s[8](#bjs10954-bib-0008){ref-type="ref"}. There was no overall difference in limb salvage or death at 1 year between initial surgery or thrombolysis[8](#bjs10954-bib-0008){ref-type="ref"}. During the past two decades, the treatment of ALI has developed appreciably with the introduction of new advanced and, more frequently, endovascular techniques[6](#bjs10954-bib-0006){ref-type="ref"}. There are no contemporary large‐scale comparisons between open and endovascular interventions for ALI. The lack of consensus on the treatment of ALI has led to wide variation in practice. Half of patients in the USA are treated with open surgery[6](#bjs10954-bib-0006){ref-type="ref"}; in contrast, in Scandinavia patients are more often treated with thrombolysis. The European Society of Vascular Surgery has initiated a process of developing clinical practice guidelines for the treatment of ALI, to be published in late 2019.

This nationwide cohort study aimed to compare short‐ and long‐term results after open or endovascular intervention for ALI, with amputation‐free survival as the primary endpoint.

Methods {#bjs10954-sec-0006}
=======

The study was approved by the regional ethical review board in Uppsala, Sweden (2014/325) and registered with prespecified outcomes at <http://clinicaltrials.gov> in July 2016 (identifier NCT02835027).

The Swedish Vascular Registry (Swedvasc) started in 1987 and has had nationwide coverage since 1994. More than 95 per cent of vascular surgical procedures performed in Sweden are registered prospectively[13](#bjs10954-bib-0013){ref-type="ref"}, [14](#bjs10954-bib-0014){ref-type="ref"}, [15](#bjs10954-bib-0015){ref-type="ref"}.

The Swedvasc database was assessed on 8 June 2015 and all patients registered with ALI between 1 January 1994 and 31 December 2014 were identified. During the target interval, the database has been updated four times, when variables were adjusted, resulting in five separate databases; these were merged. The study population was limited to patients who had an emergency or urgent admission, with symptoms of acute onset and duration less than 14 days (*Fig. S1*, supporting information). Only ALI due to occlusions below the inguinal ligament were included, to create a more homogeneous study population.

ALI secondary to trauma, dissection, bleeding or graft infection was excluded because the focus was on acute embolic or thrombotic arterial occlusions. Data are collected prospectively in the Swedvasc. The registry has been validated internally (for accuracy of data) and externally (for completeness, comparing with other databases)[13](#bjs10954-bib-0013){ref-type="ref"}, [14](#bjs10954-bib-0014){ref-type="ref"}, [15](#bjs10954-bib-0015){ref-type="ref"}.

Patients {#bjs10954-sec-0007}
--------

Patients with ALI were categorized into either initial open surgical or endovascular revascularization groups, according to the type of procedure used to treat the acute ischaemic event. The most common types of open surgery were thromboembolectomy, bypass surgery and thromboendarterectomy; the most common type of endovascular treatment was thrombolysis, often in combination with percutaneous transluminal angioplasty (PTA) and/or stenting, or stenting alone. Patients who had hybrid surgery (open and endovascular performed simultaneously) were assigned to the open group. Thus, patients in the endovascular group exclusively received endovascular surgery. If a patient was treated for ALI, with, for example, thrombolysis, and later was treated electively for the underlying lesion, the second operation was not included in the present analysis, which focused on the primary intervention alone.

Outcomes {#bjs10954-sec-0008}
--------

In Sweden, every resident has a unique personal identification number (PIN), making it possible to combine registry information, without loss to follow‐up. All deaths in Sweden are registered in the Population Registry[16](#bjs10954-bib-0016){ref-type="ref"} and lower limb amputations are registered in the National Patient Registry (NPR), which has high validity[17](#bjs10954-bib-0017){ref-type="ref"}. Accurate survival data were obtained by cross‐linking the PIN with the NPR in June 2016. The combination of these databases made it possible to obtain complete follow‐up data on mortality and amputations. Only major amputations were included in the analyses, defined as those above ankle level. Patency at 30 days was reported to the Swedvasc registry by the vascular surgeon after clinical examination, often, but not always, combined with duplex ultrasound imaging.

Definitions {#bjs10954-sec-0009}
-----------

The severity of limb ischaemia at presentation was registered in Swedvasc according to the Rutherford classification scale and the ankle : brachial pressure index[18](#bjs10954-bib-0018){ref-type="ref"}. Prospectively recorded, preoperative co‐morbidities and risk factors were: hypertension (BP over 140/90 mmHg), diabetes mellitus (treated with diet, oral medication or insulin), heart disease (history of myocardial infarction, angina pectoris, atrial fibrillation, heart failure, coronary bypass or heart valve surgery), cerebrovascular events (stroke or transient ischaemic attack), renal impairment (serum creatinine 150 mmol/l and above, or dialysis) and pulmonary disease (any diagnosed pulmonary disease).

Statistical analysis {#bjs10954-sec-0010}
--------------------

The Swedvasc database has a high completeness of registered procedures, with more than 95 per cent of all vascular surgical procedures registered prospectively; however, full information on co‐morbidities at presentation was missing for some patients (9--12 per cent). Multiple imputation to replace missing values in the database was performed using the R package mice (R Foundation for Statistical Computing, Vienna, Austria), generating 100 imputations. These imputations were analysed one at a time, pooling the results using Rubin\'s rules[19](#bjs10954-bib-0019){ref-type="ref"}. Missing information on aetiology for arterial occlusion was not completely at random. A manual chart review was performed at Uppsala University Hospital to create a model for imputing these data (*Appendix S1*, supporting information).

To select suitable co‐variables, current knowledge and directed acyclic graphs were used[20](#bjs10954-bib-0020){ref-type="ref"}. A propensity score was constructed to control for treatment selection bias. The score included aetiology of the occlusion, time interval (1994--2000, 2001--2007, 2008--2014), patient age, level of arterial occlusion, degree of ischaemia (Rutherford classification), heart disease, cerebrovascular event, renal impairment and pulmonary disease in the logistic regression model to predict the probability that the patients would receive endovascular surgery.

Next, patients from both treatment groups were matched 1 : 1 based on an estimated propensity score (the propensity scores could not differ by more than 0·001 to be considered a match). The matches were exact for aetiology of occlusion and time interval (*Appendix S1*, supporting information).

Survival distributions for matched patients were compared using Kaplan--Meier curves and the log rank test. Time at risk was calculated for each participant from the date of surgery until the date of amputation or death, or the end of the study interval (31 March 2016), whichever occurred first. Cox proportional hazards regression was used to estimate hazard ratios (HRs) for mortality, amputation and the composite endpoint: death or amputation.

Statistical significance was expressed in terms of both *P* values and 99 per cent confidence intervals. χ^2^ test was used for analysis of categorical variables and independent‐samples *t* test for continuous data. *P* \< 0·010 was considered significant. Statistical analyses were performed using the SPSS^®^ version 22.0 (IBM, Armonk, New York, USA) and R version 3.1.0.

Results {#bjs10954-sec-0011}
=======

From an initial database of 18 707 patients, 16 229 procedures in 13 308 unique patients were identified using the inclusion criteria (*Fig. S1*, supporting information). The most common reason for exclusion was suprainguinal arterial occlusion. Some 7276 treatments (44·8 per cent) were undertaken in eight university hospitals, and the remainder in county or district hospitals. The mean follow‐up was 51·6 (99 per cent c.i. 50·5 to 52·7) months.

Before propensity score matching, patients treated with open surgery were older, had more severe ischaemia, more proximal occlusions, and more often had a history of ischaemic heart disease, cerebrovascular disease and renal or respiratory insufficiency. Men, smoking, hypertension and diabetes were more common in the endovascular surgery group (*Table*  [1](#bjs10954-tbl-0001){ref-type="table"}).

###### 

Baseline characteristics before and after propensity score matching

                                   Before propensity score matching   After propensity score matching                                                      
  ------------------------------- ---------------------------------- --------------------------------- ----------- ------------------- ------------------- ----------------------------------------------
  Mean age (years)                        75·7 (75·3, 76·0)                  74·4 (74·1, 74·8)          \< 0·001†   74·5 (74·0, 75·1)   74·8 (74·3, 75·3)   0·420[†](#bjs10954-note-0101){ref-type="fn"}
  Women (%)                               50·2 (48·9, 51·5)                  46·5 (44·8, 48·0)          \< 0·001    46·2 (44·0, 48·4)   48·8 (46·6, 50·1)                      0·071
  Time interval                                                                                                                                            
  1994--2000                              35·3 (34·1, 36·6)                  24·1 (22·7, 25·5)          \< 0·001    27·0 (25·0, 29·0)   27·0 (25·0, 29·0)                      1·000
  2001--2007                              27·3 (26·1, 28·5)                  27·9 (26·4, 29·3)            0·413     28·2 (26·2, 30·2)   28·2 (26·2, 30·2)                      1·000
  2008--2014                              37·4 (36·1, 38·7)                  48·0 (46·4, 49·6)          \< 0·001    44·8 (42·6, 47·0)   44·8 (42·6, 47·0)                      1·000
  Aetiology (%)                                                                                                                                            
  Thrombosis                              43·3 (42·0, 44·6)                  69·4 (67·0, 70·9)          \< 0·001    63·7 (61·6, 65·8)   63·7 (61·6, 65·8)                      1·000
  Embolus                                 52·8 (51·5, 54·1)                  28·2 (26·8, 29·6)          \< 0·001    34·1 (32·0, 36·2)   34·1 (32·0, 36·2)                      1·000
  Popliteal aneurysm                        3·9 (3·4, 4·4)                    2·4 (1·9, 2·9)            \< 0·001     2·2 (1·5, 2·9)      2·2 (1·5, 2·9)                        1·000
  Rutherford classification (%)                                                                                                                            
  I                                        9·3 (8·6, 10·1)                   16·9 (15·7, 18·1)          \< 0·001    13·7 (12·2, 15·2)   14·5 (12·9, 16·1)                      0·381
  IIa                                     26·0 (24·8, 27·1)                  51·6 (50·0, 53·2)          \< 0·001    42·2 (40·0, 44·4)   41·9 (39·7, 44·1)                      0·838
  IIb                                     62·9 (61·7, 64·2)                  31·3 (29·8, 32·8)          \< 0·001    43·9 (41·8, 46·0)   43·3 (41·1, 45·5)                      0·671
  III                                       1·8 (1·4, 2·1)                    0·2 (0·0, 0·3)            \< 0·001     0·2 (0·1, 0·3)      0·2 (0·1, 0·2)                        0·830
  Level of occlusion (%)                                                                                                                                   
  Femoral                                 77·1 (76·0, 78·2)                  37·5 (36·0, 39·1)          \< 0·001    59·9 (57·8, 62·0)   60·6 (58·4, 62·8)                      0·565
  Popliteal                               16·4 (15·5, 17·4)                  50·7 (49·1, 52·3)          \< 0·001    29·6 (27·6, 31·6)   29·7 (27·7, 31·7)                      0·945
  Below popliteal                           6·4 (5·8, 7·1)                   11·8 (10·7, 12·8)          \< 0·001    10·5 (9·2, 11·9)     9·7 (8·3, 11·0)                       0·329
  Smoking (%)                                                                                                                                              
  Current                                 23·2 (22·1, 24·3)                  24·8 (23·5, 26·2)            0·026     24·1 (22·3, 26·0)   25·2 (23·3, 25·2)                      0·418
  Previous                                14·6 (13·7, 15·6)                  18·6 (17·3, 19·8)          \< 0·001    18·1 (16·3, 19·9)   17·6 (15·9, 19·3)                      0·706
  Never                                   62·2 (60·9, 63·5)                  56·6 (54·9, 58·2)          \< 0·001    57·8 (55·6, 60·0)   57·2 (55·0, 59·4)                      0·665
  Co‐morbidities (%)                                                                                                                                       
  Hypertension                            57·8 (56·5, 59·1)                  61·7 (60·2, 63·3)          \< 0·001    59·9 (57·7, 62·1)   61·9 (59·7, 64·0)                      0·171
  Diabetes mellitus                       20·1 (19·1, 21·1)                  23·1 (21·8, 24·5)          \< 0·001    20·0 (18·2, 21·8)   23·8 (21·9, 25·7)                      0·002
  Heart disease                           64·1 (62·9, 65·4)                  54·2 (52·7, 55·8)          \< 0·001    57·2 (55·0, 59·4)   57·2 (55·0, 59·4)                      0·972
  Cerebrovascular events                  25·8 (24·7, 26·9)                  17·6 (16·4, 18·9)          \< 0·001    18·9 (17·1, 20·6)   19·1 (17·4, 20·8)                      0·867
  Renal impairment                        11·3 (10·5, 12·1)                   7·7 (6·9, 8·6)            \< 0·001     8·3 (7·1, 9·5)      8·1 (6·9, 9·3)                        0·790
  Pulmonary disease                       16·1 (15·1, 17·1)                  13·1 (12·0, 14·2)          \< 0·001    14·3 (12·7, 15·9)   14·5 (13·0, 16·1)                      0·798

Values in parentheses are 99 per cent confidence intervals.

χ^2^ test, except

independent‐samples *t* test.

After propensity score matching, 3365 patients remained in each treatment group, and the results hereafter focus entirely on comparing these patients. Their mean age was 74·7 years (71·7 years for 3533 men, and 78·9 years for 3197 women). The only remaining difference was a higher prevalence of diabetes mellitus in the endovascular group (23·8 *versus* 20·0 per cent; *P* = 0·002) (*Table*  [1](#bjs10954-tbl-0001){ref-type="table"}).

Revascularization techniques {#bjs10954-sec-0012}
----------------------------

In the open surgery group, 61·3 per cent underwent thromboembolectomy, 25·6 per cent surgical bypass and 13·1 per cent thromboendarterectomy. In the endovascular group, 49·9 per cent underwent thrombolysis alone, 31·7 per cent thrombolysis with stent and/or percutaneous PTA, and 18·4 per cent stenting with or without PTA or subintimal angioplasty. In the open surgery group, 7·5 per cent were hybrid operations.

Early complications and patency {#bjs10954-sec-0013}
-------------------------------

Any complication during 30 days after surgery occurred in 31·3 per cent of patients after open and 22·6 per cent after endovascular revascularization (*P* \< 0·001). Bleeding complications occurred in 5·0 per cent after open and 7·1 per cent after endovascular procedures (*P* = 0·021). Perioperative stroke occurred in 0·2 and 0·4 per cent respectively (*P* = 0·190). Other complications (such as myocardial infarction and stroke) were also distributed similarly between the groups (*Table*  [2](#bjs10954-tbl-0002){ref-type="table"}). There was a trend towards more fasciotomies after open surgery (*P* = 0·014). The overall 30‐day primary patency rate was 78·6 per cent in the open and 83·0 per cent in the endovascular group (*P* \< 0·001).

###### 

Outcomes in the matched cohort

                              Overall (*n* = 6730)   Open surgery (*n* = 3365)   Endovascular treatment (*n* = 3365)   *P* [\*](#bjs10954-note-0004){ref-type="fn"}
  -------------------------- ---------------------- --------------------------- ------------------------------------- ----------------------------------------------
  Outcomes at 30 days (%)                                                                                             
  Primary patency              80·8 (79·6, 82·0)         78·6 (76·8, 80·4)                83·0 (81·4, 84·6)                              \< 0·001
  Fasciotomy                     6·4 (5·6, 7·2)           7·5 (6·3, 8·7)                   5·4 (4·4, 6·4)                                 0·014
  Myocardial infarction          2·9 (2·3, 3·5)           3·1 (2·4, 3·9)                   2·6 (1·9, 3·3)                                 0·342
  Stroke                         1·7 (1·3, 2·1)           1·4 (0·9, 1·9)                   2·1 (1·5, 2·8)                                 0·077
  Amputation                     7·6 (6·7, 8·4)           8·2 (7·0, 9·4)                   7·0 (5·9, 8·1)                                 0·113
  Death                          8·9 (8·0, 9·8)          11·1 (9·7, 12·5)                  6·7 (5·6, 7·8)                                \< 0·001
  Amputation‐free survival     84·8 (83·5, 85·8)         82·1 (80·3, 83·7)                87·5 (86·0, 88·9)                              \< 0·001
  Outcomes at 1 year (%)                                                                                              
  Amputation                   14·3 (13·2, 15·4)         14·8 (13·2, 16·4)                13·8 (12·3, 15·3)                               0·320
  Death                        24·4 (23·1, 25·7)         28·6 (26·6, 30·6)                20·2 (18·4, 22·0)                              \< 0·001
  Amputation‐free survival     65·7 (64·2, 67·2)         61·6 (59·4, 63·7)                69·9 (67·9, 71·9)                              \< 0·001

Values in parentheses are 99 per cent confidence intervals.

χ^2^ test.

Main outcomes {#bjs10954-sec-0014}
-------------

The amputation rate at 30 days was 7·0 per cent after endovascular and 8·2 per cent after open surgery (*P* = 0·113). Respective 30‐day mortality rates were 6·7 and 11·1 per cent (*P* \< 0·001). The amputation‐free survival rate was 87·5 per cent after endovascular and 82·1 per cent after open treatment (*P* \< 0·001). The same pattern was observed 1 year after surgery: similar amputation rates but superior survival and amputation‐free survival after endovascular surgery (*Table*  [2](#bjs10954-tbl-0002){ref-type="table"}). The 1‐year risk of death was 28·6 per cent after open surgery and 20·2 per cent in the endovascular group (*P* \< 0·001). This risk difference corresponded to a number needed to treat of 12 patients to prevent one death within the first year, if primary treatment was changed from open to endovascular surgery.

Cox regression analyses revealed the same pattern at 30 days, 1 year and 5 years after surgery (*Table*  [3](#bjs10954-tbl-0003){ref-type="table"}). At 5 years, the endovascular group had lower mortality rates (HR 0·78, 99 per cent c.i. 0·70 to 0·86) and superior amputation‐free survival (HR 0·82, 0·75 to 0·90).

###### 

Hazard ratios for amputation and death after endovascular treatment *versus* open surgery

                             Hazard ratio for endovascular treatment *versus* open surgery     *P*
  ------------------------- --------------------------------------------------------------- ----------
  Outcomes at 30 days                                                                       
  Amputation                                       0·84 (0·65, 1·10)                          0·098
  Death                                            0·58 (0·45, 0·74)                         \< 0·001
  Amputation and/or death                          0·67 (0·56, 0·81)                         \< 0·001
  Outcomes at 1 year                                                                        
  Amputation                                       0·92 (0·76, 1·12)                          0·270
  Death                                            0·66 (0·57, 0·77)                         \< 0·001
  Amputation and/or death                          0·73 (0·65, 0·83)                         \< 0·001
  Outcomes at 5 years                                                                       
  Amputation                                       1·01 (0·85, 1·19)                          0·937
  Death                                            0·78 (0·70, 0·86)                         \< 0·001
  Amputation and/or death                          0·82 (0·75, 0·90)                         \< 0·001

Values in parentheses are 99 per cent confidence intervals. The analysis included 3365 patients in each group. Hazard ratios were calculated using Cox proportional hazards regression.

A landmark analysis was performed starting 1 year after index surgery to interpret the remaining effect of the intervention after events from the first year had been excluded. When time censoring was set at 5 years, there was no statistically significant difference in the risk of adverse events after endovascular treatment compared with open surgery: amputation (HR 1·45, 99 per cent c.i. 0·96 to 2·17), death (HR 0·90, 0·78 to 1·04) and amputation and/or death (HR 0·96, 0·83 to 1·12).

Curves for amputation were similar in the two treatment groups up to 10 years after the intervention (*P* = 0·322) (*Fig*. [1](#bjs10954-fig-0001){ref-type="fig"} *a*). There were significant differences between the groups in overall and amputation‐free survival (both *P \<* 0·001) (*Fig*. [1](#bjs10954-fig-0001){ref-type="fig"} *b*,*c*). The survival curves showed a difference between the treatment groups during the first year of follow‐up. Thereafter, mortality rates were similar.

![Kaplan--Meier curves comparing **a** freedom from amputation, **b** overall survival and **c** amputation‐free survival after open or endovascular revascularization. **a** *P* = 0·322, **b**,**c** *P* \< 0·001 (log rank test)](BJS-105-1598-g003){#bjs10954-fig-0001}

In a sensitivity analysis, amputation‐free survival after endovascular and open surgery was investigated by type of arterial occlusion (*Fig. S2*, supporting information). The amputation‐free survival rate was higher after endovascular intervention, irrespective of whether the ALI was caused by embolic or thrombotic occlusion (*P* \< 0·001).

Discussion {#bjs10954-sec-0015}
==========

ALI is a severe condition threatening both life and limb. The present study demonstrated similar amputation rates, but improved survival after primary endovascular intervention compared with open surgery. The results suggest that one life could be saved during the first year, if the primary treatment were changed from open to endovascular in 12 patients.

In the mid‐1990s, three randomized trials addressed the optimal treatment strategy for patients with ALI. A Cochrane database meta‐analysis of the studies[8](#bjs10954-bib-0008){ref-type="ref"} concluded that there was no overall difference in limb salvage, death or amputation‐free survival at 30 days or 1 year. A limitation of this meta‐analysis was the low precision of the estimates.

Ouriel and colleagues[21](#bjs10954-bib-0021){ref-type="ref"} randomized 114 patients with ALI of less than 7 days\' duration to thrombolysis with urokinase or open surgery. At 1 year, the cumulative risk of amputation (18 per cent) was equal in the two groups, whereas thrombolysis was associated with a reduction in mortality. The STILE (Surgery *versus* Thrombolysis for Ischaemia of the Lower Extremity) trial[11](#bjs10954-bib-0011){ref-type="ref"} randomized 393 patients with non‐embolic lower extremity ischaemia of less than 6 months\' duration. A higher percentage of patients randomized to thrombolysis had treatment failure at 30 days, which led to premature termination of the trial. Most patients in the STILE trial, however, had chronic ischaemia. Subsequent subgroup analysis indicated that patients presenting with acute ischaemia (symptoms for less than 14 days) and randomized to thrombolysis had significantly better limb salvage (89 *versus* 70 per cent) and amputation‐free survival. Finally, the TOPAS (Thrombolysis or Peripheral Arterial Surgery) trial[22](#bjs10954-bib-0022){ref-type="ref"}, [23](#bjs10954-bib-0023){ref-type="ref"} randomized 544 patients with acute lower extremity ischaemia secondary to native arterial or bypass graft occlusion of less than 14 days\' duration. Survival and amputation‐free survival rates at 12 months were similar, but significantly more bleeding occurred in those randomized to urokinase.

The present study compared first‐line endovascular treatment with open surgery. There was a trend towards more bleeding complications associated with endovascular treatment; however, stroke/intracranial haemorrhage rates were similar in the two groups.

One year after intervention and beyond, the two survival curves were parallel, indicating that the propensity score match was successful in addressing confounding and selection bias. The difference in effects of the two treatments occurred closer to the intervention. The landmark analysis confirmed the lack of difference in risk of late events, although there was a trend towards more late amputations after endovascular intervention. Results from the landmark analysis should be interpreted with caution, however, as the co‐variable balance achieved by the propensity score matching might no longer be accurate.

It was predicted that the advantage of endovascular treatment could be more pronounced in patients with a thrombotic occlusion, but subgroup analysis suggested the opposite (*Fig. S2*, supporting information). The advantage of the less invasive technique seemed to be in the most vulnerable patients with embolic occlusions.

There are a number of possible reasons why endovascular treatment may offer additional advantages. First, it can be done under local anaesthesia, which is convenient because many patients with ALI are elderly and fragile with multiple co‐morbidities[4](#bjs10954-bib-0004){ref-type="ref"}. Second, endovascular treatment includes accurate angiographic imaging, and possibly a more directed and definitive therapeutic approach[24](#bjs10954-bib-0024){ref-type="ref"}. It also ensures a completion control at the end of the procedure, which is not always the case after open surgery.

Several studies[7](#bjs10954-bib-0007){ref-type="ref"}, [11](#bjs10954-bib-0011){ref-type="ref"}, [22](#bjs10954-bib-0022){ref-type="ref"} have reported that initial thrombolytic therapy can reduce the need for subsequent surgical treatment. If unsuccessful, thrombolysis can be followed promptly by surgery, whereas the reverse order is contraindicated owing to the risk of bleeding[4](#bjs10954-bib-0004){ref-type="ref"}. A noteworthy observation from the STILE trial[11](#bjs10954-bib-0011){ref-type="ref"} was that patients in whom surgery failed had more than twice the risk of major amputation compared with those who had initial unsuccessful thrombolysis.

For patients with severe ischaemia and a motor deficit (Rutherford class IIb), the previous recommendation[25](#bjs10954-bib-0025){ref-type="ref"} has been urgent surgery because of the relatively long time required for revascularization with thrombolysis. Emergency lower extremity bypass for ALI, however, is associated with increased rates of serious in‐hospital adverse events, major amputation rates and mortality compared with elective bypass surgery[26](#bjs10954-bib-0026){ref-type="ref"}. There are several possible explanations for these difficulties, including a lack of time for preoperative optimization, longer procedures, greater blood loss and the use of a prosthetic conduit[26](#bjs10954-bib-0026){ref-type="ref"}. In recent years, several endovascular solutions have evolved for more severe ischaemia, with the introduction of aspiration, percutaneous mechanical thrombectomy and rheolytic techniques. Percutaneous mechanical devices enhance the surgeon\'s ability to remove thrombus quickly, resulting in lower doses of thrombolytic drugs and reducing the time to reperfusion[1](#bjs10954-bib-0001){ref-type="ref"}. Some studies[27](#bjs10954-bib-0027){ref-type="ref"}, [28](#bjs10954-bib-0028){ref-type="ref"} have indicated that, when rapid reperfusion is needed, percutaneous local mechanical thrombectomy, with or without thrombolysis, may be used in a safe and efficient way, even in patients with severe ischaemia and a motor deficit. Endovascular treatment may also serve as a valuable first‐line approach, which can be followed later in elective settings by surgical treatment when the patient and circumstances have been optimized[29](#bjs10954-bib-0029){ref-type="ref"}.

A sizeable proportion of the patients treated here using endovascular methods had severe ischaemia with neurological symptoms (Rutherford class IIb). Many of the patients with the most severe ischaemia (Rutherford class IIb and III) were, however, excluded by the propensity score matching because most were treated with open surgery. After propensity score matching, severe ischaemia occurred in approximately 44 per cent in both groups (*Table*  [1](#bjs10954-tbl-0001){ref-type="table"}). During the study, a shift towards more endovascular and hybrid revascularization techniques was observed (*Fig. S3*, supporting information).

The major limitation of this study was the observational design. Propensity score matching is a useful tool to account for observed differences between two treatment groups in order to isolate the effect of a treatment; however, propensity scores cannot adjust for unobserved differences between groups. It is possible that unobserved co‐variables might have influenced the choice of treatment as well as the outcome, a phenomenon labelled residual confounding. Furthermore, the distinction between thrombosis and embolus can sometimes be difficult, especially in an ageing population that often has established atherosclerotic disease of the arteries. When a patient presents with both lower limb atherosclerosis and a source of embolus, not only classification but also treatment is complex[4](#bjs10954-bib-0004){ref-type="ref"}.

In this large propensity score‐matched nationwide cohort study, primary endovascular treatment of ALI appears to be beneficial, with significantly better short‐term survival and amputation‐free survival compared with primary open revascularization.
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